In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target of $110.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Charles Zhu has given his Buy rating due to a combination of factors that highlight the promising potential of Nuvalent’s zidesamib as a best-in-class ROS1 TKI. The recent update from Nuvalent showcased strong efficacy data in TKI-pretreated ROS1+ NSCLC patients, with notable objective response rates (ORR) in various patient groups, including those with prior TKI treatments. This efficacy is complemented by impressive durability, with a high percentage of patients maintaining their response over extended periods.
Furthermore, preliminary data from TKI-naive cohorts also indicate robust outcomes, reinforcing the drug’s potential. Safety profiles remain favorable, with low rates of treatment-emergent adverse events and minimal need for dose adjustments or discontinuations. Management’s confidence in zidesamib’s activity, mutation coverage, CNS penetration, and selectivity further supports the Buy rating, as these factors collectively underscore the differentiated efficacy, durability, and safety of the treatment.
In another report released on June 18, Barclays also maintained a Buy rating on the stock with a $100.00 price target.